CTIS2023-506541-39-00进行中（未招募）1 期
20160323
Amgen Inc.0 个研究点目标入组 377 人开始时间: 2024年6月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 377
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, four period, two-sequence, multiple-dose (steady-state), fully-replicate crossover bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fasting condition.CTIS2024-512770-10-00Sun Pharmaceutical Industries Limited50
招募中
1 期
Effect of botulinum toxin on hamstring contracture and the occurrence of cyclops syndrome following anterior cruciate ligament reconstructioCyclops syndromeMedDRA version: 20.0Level: PTClassification code: 10058029Term: Arthrofibrosis Class: 100000004859CTIS2023-509193-32-01Ramsay Generale De Sante132
进行中（未招募）
1 期
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)CTIS2023-506975-83-00Aprogen Inc.720
进行中（未招募）
1 期
AAMedDRA version: 20.0 Level: LLT Classification code 10028566 Term: Myeloma System Organ Class: 100000004864EUCTR2017-001446-10-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)35
招募中
1 期
Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate CancerCTIS2023-504361-23-00Amgen Inc.461